GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With C...(ASH (Abstract #401 Abstract #669) ...),Health

A post hoc analysis of data from the ongoing EXTEND (Eltrombopag eXTENded Dosing study) trial of refractory and non-refractory ITP patients showed that PROMACTA induced long-lasting platelet count increases and reduced clinically significant bleeding symptoms. The analysis is being presented at ASH on Monday, December 8, 2008 at 12:00 noon, PST.

In addition, data from a survey of ITP patients showed that patients are willing to accept significant risks for treatment side effects in exchange for improved efficacy and convenient administration. The survey results are being presented at ASH on Monday, December 8, 2008 at 4:30 p.m., PST.

About PROMACTA

PROMACTA is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets.

PROMACTA was discovered as a result of a research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq: LGND). It was developed by GlaxoSmithKline. GSK plans to submit a Marketing Authorization Application (MAA) for eltrombopag in Europe in 2008.

Important Safety Information

BOXED WARNING

PROMACTA may cause hepatotoxicity. Patients receiving therapy with PROMACTA must have regular monitoring of serum liver tests (see Laboratory Monitoring below). Discontinue PROMACTA if ALT levels increase to greater than or equal to 3X upper limit of normal (ULN) and are: progressive; or persistent for greater than or equal to 4 weeks, or; accompanied by increased direct bilirubin; or accompanied by clinical symptoms of liver injury or evidence for hepatic decompensation. Reinitiating treatment with PROMACTA
'/>"/>